Business Context and Reporting Period
This Form 6-K filing by Prana Biotechnology Limited (noted as Altery Therapeutics Ltd in metadata) covers the month of May 2004. The registrant is a foreign private issuer based in South Melbourne, Victoria, Australia. The filing primarily serves as a new issue announcement and application for quotation of additional securities with the Australian Securities Exchange (ASX).
Key Financial Metrics and Capital Structure
The filing details a specific equity issuance rather than providing comprehensive financial statements (revenue, profit, or cash flow are not reported in this document).
- Securities Issued: 300,000 Ordinary Shares.
- Issue Price: $0.50 per share.
- Purpose of Issue: Exercise of options (specifically classes PBTAK and PBTAO).
- Terms: New shares rank pari passu with existing ordinary shares.
- Existing Capital Structure (Quoted): 74,959,380 Ordinary Shares.
- Outstanding Options (Unquoted):
- 19,750,000 options exercisable at $0.50 (expiry: 1 Dec 2004).
- 1,097,167 Employee & Consultant options exercisable at $0.50 (expiry: 30 June 2005).
- 10,000 Employee & Consultant options exercisable at $1.50 (expiry: 30 June 2005).
- 200,000 options exercisable at $0.50 (expiry: 1 Oct 2005).
Material Changes
The primary material change is the increase in the number of issued ordinary shares by 300,000 following the exercise of options on 20 April 2004. The filing confirms that the dividend policy remains unchanged following this capital increase.
Outlook, Risks, and Management Commentary
The filing contains no management commentary regarding business outlook, risks, or contingencies. It is a procedural document confirming compliance with ASX listing rules for the new issue. The registrant warrants that the issue complies with applicable laws and that no illegal purpose is served. The filing notes that information not currently available will be provided to the ASX as soon as it becomes available.
Investor Verification Checklist
- Verify the total number of outstanding shares post-issuance (74,959,380 + 300,000).
- Confirm the dilution impact of the 300,000 new shares relative to the existing float.
- Review the expiration dates and exercise prices of the remaining 21 million+ options to assess future dilution potential.
- Check subsequent filings for the actual cash proceeds received from the $0.50 per share exercise price.
- Confirm the company's current operational status, as this filing provides no revenue or profit data.